Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MUC16 elevation
i
Other names:
MUC16, Mucin 16, Cell Surface Associated, Ovarian Cancer-Related Tumor Marker CA125, Ovarian Carcinoma Antigen CA125, Mucin-16, CA125, CA125 Ovarian Cancer Antigen, Mucin-16 Short Isoform, Mucin-16 Long Isoform, CA-125, MUC-16
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
94025
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) (NCT05445778)
Phase 3
ImmunoGen, Inc.
ImmunoGen, Inc.
Recruiting
Phase 3
ImmunoGen, Inc.
Recruiting
Last update posted :
06/13/2024
Initiation :
12/27/2022
Primary completion :
03/01/2027
Completion :
04/01/2029
FOLR1 • BRCA • MUC16
|
FOLR1 expression • MUC16 elevation
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy (NCT06083844)
Phase 2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Recruiting
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/30/2024
Initiation :
12/12/2023
Primary completion :
09/30/2025
Completion :
09/30/2027
BRCA1 • BRCA2 • MUC16
|
MUC16 elevation
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • cyclophosphamide
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection (NCT05334069)
Phase N/A
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Recruiting
Phase N/A
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
05/23/2024
Initiation :
08/01/2022
Primary completion :
01/31/2025
Completion :
02/01/2025
MUC16
|
MUC16 elevation
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer (NCT05051722)
Phase N/A
Mayo Clinic
Mayo Clinic
Recruiting
Phase N/A
Mayo Clinic
Recruiting
Last update posted :
05/16/2024
Initiation :
08/03/2021
Primary completion :
06/30/2025
Completion :
12/30/2025
MUC16
|
MUC16 elevation
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (FRAGILE) (NCT02828618)
Phase N/A
AGO Study Group
AGO Study Group
Active, not recruiting
Phase N/A
AGO Study Group
Active, not recruiting
Last update posted :
05/09/2024
Initiation :
07/01/2016
Primary completion :
12/01/2024
Completion :
02/01/2025
MUC16
|
MUC16 elevation
Combination Therapy for Recurrent Ovarian Cancer (NCT05610735)
Phase 1/2
Sham Sunder Kakar
Sham Sunder Kakar
Recruiting
Phase 1/2
Sham Sunder Kakar
Recruiting
Last update posted :
04/24/2024
Initiation :
05/01/2024
Primary completion :
11/01/2026
Completion :
11/01/2027
MUC16
|
MUC16 elevation
|
pegylated liposomal doxorubicin
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/08/2024
Initiation :
04/14/2010
Primary completion :
10/31/2018
Completion :
02/13/2025
BRCA • MUC16
|
BRCA mutation • MUC16 elevation
|
Lynparza (olaparib) • Recentin (cediranib)
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00408590)
Phase 1
Mayo Clinic
Mayo Clinic
Completed
Phase 1
Mayo Clinic
Completed
Last update posted :
01/15/2024
Initiation :
04/19/2004
Primary completion :
08/01/2012
Completion :
11/07/2017
MUC16 • CD4
|
MUC16 elevation
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers (NCT00803569)
Phase 1
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Completed
Phase 1
Ludwig Institute for Cancer Research
Completed
Last update posted :
10/04/2023
Initiation :
11/14/2008
Primary completion :
01/24/2011
Completion :
01/24/2011
MUC16 • CTAG1B • CTAG2
|
MUC16 elevation
|
Leukine (sargramostim)
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707)
Phase 1
Mayo Clinic
Mayo Clinic
Active, not recruiting
Phase 1
Mayo Clinic
Active, not recruiting
Last update posted :
10/02/2023
Initiation :
02/24/2014
Primary completion :
06/30/2024
Completion :
06/30/2025
MUC16
|
MUC16 elevation
|
Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02122185)
Phase 2
University of Chicago
University of Chicago
Suspended
Phase 2
University of Chicago
Suspended
Last update posted :
08/28/2023
Initiation :
02/25/2015
Primary completion :
02/25/2025
Completion :
02/25/2025
CEACAM5 • MUC16
|
MUC16 elevation
|
metformin
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (NCT06014528)
Phase 2
InxMed (Shanghai) Co., Ltd.
InxMed (Shanghai) Co., Ltd.
Recruiting
Phase 2
InxMed (Shanghai) Co., Ltd.
Recruiting
Last update posted :
08/28/2023
Initiation :
09/06/2022
Primary completion :
12/01/2024
Completion :
12/01/2025
MUC16
|
MUC16 elevation
|
pegylated liposomal doxorubicin • ifebemtinib (IN10018)
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (NCT04111978)
Phase 3
Swiss GO Trial Group
Swiss GO Trial Group
Recruiting
Phase 3
Swiss GO Trial Group
Recruiting
Last update posted :
06/27/2023
Initiation :
11/05/2020
Primary completion :
10/01/2025
Completion :
10/01/2030
ER • MUC16
|
MUC16 elevation
|
letrozole
Phase I Study of MOv18 IgE (CRUKD14/001) (NCT02546921)
Phase 1
Cancer Research UK
Cancer Research UK
Completed
Phase 1
Cancer Research UK
Completed
Last update posted :
06/05/2023
Initiation :
02/16/2016
Primary completion :
06/22/2021
Completion :
07/30/2021
MUC16
|
MUC16 elevation
|
MOv18 IgE
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (NCT02759588)
Phase 1b
Genelux Corporation
Genelux Corporation
Completed
Phase 1b
Genelux Corporation
Completed
Last update posted :
01/05/2023
Initiation :
05/01/2016
Primary completion :
12/31/2021
Completion :
12/31/2022
MUC16
|
MUC16 elevation
|
Avastin (bevacizumab) • olvimulogene nanivacirepvec (GL-ONC1)
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) (NCT03278717)
Phase 3
University College, London
University College, London
Recruiting
Phase 3
University College, London
Recruiting
Last update posted :
09/27/2022
Initiation :
06/15/2018
Primary completion :
12/01/2023
Completion :
12/01/2023
BRCA • MUC16
|
BRCA mutation • MUC16 elevation
|
Lynparza (olaparib) • Recentin (cediranib)
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer (NCT03056833)
Phase 1
Ronald Buckanovich
Ronald Buckanovich
Completed
Phase 1
Ronald Buckanovich
Completed
Last update posted :
09/07/2022
Initiation :
06/10/2017
Primary completion :
06/01/2020
Completion :
08/01/2022
MUC16
|
MUC16 elevation
|
carboplatin • paclitaxel • Kisqali (ribociclib)
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer (NCT03794778)
Phase 4
Women's Hospital School Of Medicine Zhejiang University
Women's Hospital School Of Medicine Zhe...
Active, not recruiting
Phase 4
Women's Hospital School Of Medicine Zhejiang Un...
Active, not recruiting
Last update posted :
07/18/2022
Initiation :
03/19/2019
Primary completion :
03/31/2024
Completion :
03/31/2024
MUC16
|
MUC16 elevation
|
carboplatin • paclitaxel • pegylated liposomal doxorubicin • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors (GYNO-MIR) (NCT03776630)
Phase N/A
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Active, not recruiting
Phase N/A
Assistance Publique - Hôpitaux de Paris
Active, not recruiting
Last update posted :
06/30/2022
Initiation :
05/23/2019
Primary completion :
05/01/2023
Completion :
05/01/2027
MUC16 • MIR200B
|
MUC16 elevation
Safety Study of X-82 in Patients With Advanced Solid Tumors (NCT01296581)
Phase 1
Tyrogenex
Tyrogenex
Completed
Phase 1
Tyrogenex
Completed
Last update posted :
02/28/2022
Initiation :
02/01/2011
Primary completion :
01/01/2014
Completion :
01/01/2017
MUC16
|
MUC16 elevation
|
Fumena (vorolanib)
DDP ip Combined With AG in PDAC With Peritoneal Metastasis (NCT05222204)
Phase 2
Fudan University
Fudan University
Recruiting
Phase 2
Fudan University
Recruiting
Last update posted :
02/03/2022
Initiation :
07/02/2021
Primary completion :
07/02/2023
Completion :
07/02/2023
MUC16
|
MUC16 elevation
|
cisplatin • gemcitabine • albumin-bound paclitaxel
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer (NCT04518501)
Phase 1/2
Xing Xie
Xing Xie
Recruiting
Phase 1/2
Xing Xie
Recruiting
Last update posted :
01/25/2022
Initiation :
07/01/2020
Primary completion :
01/01/2024
Completion :
01/01/2025
BRCA1 • BRCA2 • MUC16
|
BRCA2 mutation • BRCA1 mutation • MUC16 elevation
|
Lynparza (olaparib) • AiRuiYi (fluzoparib) • arsenic trioxide
Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer (QUALOV) (NCT04826029)
Phase N/A
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Withdrawn
Phase N/A
Assistance Publique - Hôpitaux de Paris
Withdrawn
Last update posted :
12/10/2021
Initiation :
06/22/2021
Primary completion :
06/22/2021
Completion :
06/22/2021
BRCA • MUC16
|
MUC16 elevation
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer (NCT04217798)
Phase 2
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Recruiting
Phase 2
Peking Union Medical College Hospital
Recruiting
Last update posted :
09/01/2021
Initiation :
05/21/2020
Primary completion :
03/01/2022
Completion :
06/01/2022
MUC16
|
MUC16 elevation
|
Zejula (niraparib) • etoposide oral
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer (OVACURE) (NCT04072263)
Phase 1/2
Leiden University Medical Center
Leiden University Medical Center
Recruiting
Phase 1/2
Leiden University Medical Center
Recruiting
Last update posted :
04/01/2021
Initiation :
08/01/2018
Primary completion :
08/01/2021
Completion :
12/01/2021
MUC16
|
MUC16 elevation
|
carboplatin • paclitaxel
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00866697)
Phase 3
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Completed
Phase 3
Novartis Pharmaceuticals
Completed
Last update posted :
02/16/2021
Initiation :
05/26/2009
Primary completion :
07/08/2012
Completion :
08/24/2017
MUC16
|
MUC16 elevation
|
pazopanib
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (AVANIRA3) (NCT04556071)
Phase 2
Xiaoxiang Chen
Xiaoxiang Chen
Recruiting
Phase 2
Xiaoxiang Chen
Recruiting
Last update posted :
11/10/2020
Initiation :
11/06/2020
Primary completion :
03/01/2022
Completion :
10/01/2022
HRD • MUC16
|
HRD • MUC16 elevation
|
Avastin (bevacizumab) • Zejula (niraparib)
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT02283658)
Phase 2
Mayo Clinic
Mayo Clinic
Completed
Phase 2
Mayo Clinic
Completed
Last update posted :
10/23/2020
Initiation :
11/14/2014
Primary completion :
06/15/2016
Completion :
06/21/2018
ER • MUC16
|
ER positive • MUC16 elevation
|
everolimus • letrozole
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) (NCT00889382)
Phase 1/2
Astellas Pharma Inc
Astellas Pharma Inc
Completed
Phase 1/2
Astellas Pharma Inc
Completed
Last update posted :
11/19/2019
Initiation :
08/05/2009
Primary completion :
08/01/2014
Completion :
08/25/2014
MUC16
|
MUC16 elevation
|
paclitaxel • linsitinib (ASP7487)
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01747798)
Phase 1
Mayo Clinic
Mayo Clinic
Completed
Phase 1
Mayo Clinic
Completed
Last update posted :
08/02/2019
Initiation :
11/02/2012
Primary completion :
01/10/2014
Completion :
04/06/2015
MUC16
|
MUC16 elevation
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
07/23/2019
Initiation :
12/01/2009
Primary completion :
07/01/2012
Completion :
07/29/2012
MUC16
|
MUC16 elevation
|
cisplatin • carboplatin • Beleodaq (belinostat)
Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer (NCT00511641)
Phase N/A
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Unknown status
Phase N/A
M.D. Anderson Cancer Center
Unknown status
Last update posted :
06/24/2019
Initiation :
02/12/2002
Primary completion :
02/01/2020
Completion :
02/01/2021
MUC16
|
MUC16 elevation
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01489371)
Phase 1
Gynecologic Oncology Group
Gynecologic Oncology Group
Completed
Phase 1
Gynecologic Oncology Group
Completed
Last update posted :
03/12/2019
Initiation :
07/09/2012
Primary completion :
12/30/2014
Completion :
01/27/2018
MUC16
|
MUC16 elevation
|
cisplatin • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer (NCT00278343)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
08/29/2018
Initiation :
04/01/2006
Primary completion :
06/01/2010
Completion :
01/15/2018
MUC16
|
MUC16 elevation
|
Recentin (cediranib)
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (NCT01223235)
Phase N/A
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Completed
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
06/12/2018
Initiation :
10/01/2010
Primary completion :
09/01/2017
Completion :
09/01/2017
ALK • MUC16
|
MUC16 elevation
|
Avastin (bevacizumab) • polyvalent vaccine-KLH conjugate
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login